Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 82 Lung Neoplasms 24 Brain Neoplasms 6 NSCLC 5 Meningeal Carcinomatosis 3 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Non Small Cell Lung Cancer Metastatic 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Lymphoma 2 Hematologic Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma 2 Adenocarcinoma of Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Stage II-IIIB Non-small Cell Lung Carcinoma 1 Resectable Non-small Cell Lung Cancer 1 Rectal Neoplasms 1 Rare Tumour 1 Non-Small Cell Lung Cancer With EGFR T790M Mutation 1 Neurocognitive 1 Melanoma 1 Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1 Glioma 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × osimertinib × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡